Literature DB >> 20156136

Transporter-mediated multidrug resistance and its modulation by Chinese medicines and other herbal products.

Zhijun Wang1, Ranadheer Ravula, Mingju Cao, Moses Chow, Ying Huang.   

Abstract

The main cause of failure in cancer drug therapy is the emergence of cellular resistance to drugs. Cancer cells, after exposure to one drug, can become simultaneously insensitive to mechanistically and chemically unrelated drugs, a phenotype known as multidrug resistance (MDR). Although a number of mechanisms have been proposed to mediate MDR, the classical cellular mechanism involves the overexpression of several members of the ATP-binding cassette (ABC) superfamily of transporters, leading to increased efflux and decreased intracellular drug accumulation. Among these, P-glycoprotein (P-gp, ABCB1), MRP1 (ABCC1) and BCRP (ABCG2) are the main transporters conferring MDR. These transporters are frequently detected in recurrent cancer cells or cancer stem cells. To overcome MDR, various studies have been conducted to investigate potential to discover effective MDR modulators from Chinese medicines (CMs) and other herbal products because many of these have been used for centuries without harmful side effects. This review summarizes: i) The contribution of P-gp, MRP1 and BCRP in cancer drug resistance; ii) known mechanisms of action for MDR modulators; iii) commonly used methods for identification and evaluation of novel modulators of transporter-mediated MDR; and iv) the modulating effects of CMs and other natural products on ABC transporters and MDR. The CM and their active components with potent modulating effects on MDR can be considered as promising lead agents for the design of more effective and less toxic drugs to overcome MDR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20156136     DOI: 10.2174/157016310791162712

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  6 in total

1.  Attenuation of lung cancer stem cell tumorigenesis and metastasis by cisplatin.

Authors:  Shenxu Wang; Sai Ma; Xiujuan Li; Zengfu Xue; Xiaotian Zhang; Weiwei Fan; Yongzhan Nie; Kaichun Wu; Xiaoyuan Chen; Feng Cao
Journal:  Exp Lung Res       Date:  2014-08-25       Impact factor: 2.459

2.  Chemosensitizing Effect and Efficacy of Wilforlide A in Combination With Docetaxel in Drug-resistant Prostate Cancer.

Authors:  Zhijun Wang; Steven Yeung; Shanchao Yang; Ying Huang; Moses Sing Sum Chow
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

3.  Enhanced anti-tumor efficacy and mechanisms associated with docetaxel-piperine combination- in vitro and in vivo investigation using a taxane-resistant prostate cancer model.

Authors:  Chenrui Li; Zhijun Wang; Qian Wang; Rebecca Lucinda Ka Yan Ho; Ying Huang; Moses S S Chow; Christopher Wai Kei Lam; Zhong Zuo
Journal:  Oncotarget       Date:  2017-12-14

4.  Overcoming chemoresistance in prostate cancer with Chinese medicine Tripterygium wilfordii via multiple mechanisms.

Authors:  Zhijun Wang; Ranadheer Ravula; Leming Shi; Yunjie Song; Steven Yeung; Mandy Liu; Bernard Lau; Jijun Hao; Jeffrey Wang; Christopher Wai Kei Lam; Moses Sing Sum Chow; Ying Huang
Journal:  Oncotarget       Date:  2016-09-20

5.  Inhibitory Effect of Crocin Against Gastric Carcinoma via Regulating TPM4 Gene.

Authors:  Yushuang Luo; Pengjie Yu; Junhui Zhao; Qijing Guo; Baohua Fan; Yinzhuo Diao; Yulong Jin; Jing Wu; Chengwu Zhang
Journal:  Onco Targets Ther       Date:  2021-01-07       Impact factor: 4.147

Review 6.  Notch signaling in female cancers: a multifaceted node to overcome drug resistance.

Authors:  Maria V Giuli; Angelica Mancusi; Eugenia Giuliani; Isabella Screpanti; Saula Checquolo
Journal:  Cancer Drug Resist       Date:  2021-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.